vs

Side-by-side financial comparison of Biofrontera Inc. (BFRI) and Fortress Biotech, Inc. (FBIO). Click either name above to swap in a different company.

Biofrontera Inc. is the larger business by last-quarter revenue ($17.1M vs $16.1M, roughly 1.1× Fortress Biotech, Inc.). Biofrontera Inc. runs the higher net margin — 33.0% vs -24.5%, a 57.5% gap on every dollar of revenue. On growth, Biofrontera Inc. posted the faster year-over-year revenue change (36.2% vs 6.3%). Over the past eight quarters, Biofrontera Inc.'s revenue compounded faster (47.0% CAGR vs 11.0%).

Biofrontera Inc. is a specialty biopharmaceutical enterprise focused on developing and commercializing prescription dermatological products. Its core product line targets skin conditions including actinic keratosis and other dermatological disorders, with primary operating markets in the United States and European Union, serving patients and dermatology care providers.

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

BFRI vs FBIO — Head-to-Head

Bigger by revenue
BFRI
BFRI
1.1× larger
BFRI
$17.1M
$16.1M
FBIO
Growing faster (revenue YoY)
BFRI
BFRI
+29.9% gap
BFRI
36.2%
6.3%
FBIO
Higher net margin
BFRI
BFRI
57.5% more per $
BFRI
33.0%
-24.5%
FBIO
Faster 2-yr revenue CAGR
BFRI
BFRI
Annualised
BFRI
47.0%
11.0%
FBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BFRI
BFRI
FBIO
FBIO
Revenue
$17.1M
$16.1M
Net Profit
$5.6M
$-3.9M
Gross Margin
66.1%
Operating Margin
26.6%
-28.8%
Net Margin
33.0%
-24.5%
Revenue YoY
36.2%
6.3%
Net Profit YoY
504.0%
41.8%
EPS (diluted)
$0.62
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFRI
BFRI
FBIO
FBIO
Q4 25
$17.1M
$16.1M
Q3 25
$7.0M
$17.6M
Q2 25
$9.0M
$16.4M
Q1 25
$8.6M
$13.1M
Q4 24
$12.6M
$15.1M
Q3 24
$9.0M
$14.6M
Q2 24
$7.8M
$14.9M
Q1 24
$7.9M
$13.0M
Net Profit
BFRI
BFRI
FBIO
FBIO
Q4 25
$5.6M
$-3.9M
Q3 25
$-6.6M
$5.8M
Q2 25
$-5.3M
$15.5M
Q1 25
$-4.2M
$-10.6M
Q4 24
$-1.4M
$-6.8M
Q3 24
$-5.7M
$-12.9M
Q2 24
$-257.0K
$-10.9M
Q1 24
$-10.4M
$-15.4M
Gross Margin
BFRI
BFRI
FBIO
FBIO
Q4 25
66.1%
Q3 25
67.4%
Q2 25
69.9%
Q1 25
63.5%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Q1 24
53.9%
Operating Margin
BFRI
BFRI
FBIO
FBIO
Q4 25
26.6%
-28.8%
Q3 25
-89.8%
-38.6%
Q2 25
-56.2%
-222.2%
Q1 25
-52.9%
-169.9%
Q4 24
-13.6%
-158.3%
Q3 24
-55.0%
-151.0%
Q2 24
-64.7%
-186.5%
Q1 24
-69.1%
-280.6%
Net Margin
BFRI
BFRI
FBIO
FBIO
Q4 25
33.0%
-24.5%
Q3 25
-95.1%
33.2%
Q2 25
-59.0%
94.4%
Q1 25
-48.9%
-80.6%
Q4 24
-11.1%
-44.7%
Q3 24
-62.9%
-88.0%
Q2 24
-3.3%
-73.5%
Q1 24
-131.9%
-118.3%
EPS (diluted)
BFRI
BFRI
FBIO
FBIO
Q4 25
$0.62
$-0.15
Q3 25
$-0.62
$0.11
Q2 25
$-0.57
$0.45
Q1 25
$-0.47
$-0.48
Q4 24
$0.69
$-0.16
Q3 24
$-0.98
$-0.76
Q2 24
$-0.05
$-0.73
Q1 24
$-2.88
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFRI
BFRI
FBIO
FBIO
Cash + ST InvestmentsLiquidity on hand
$6.4M
$79.4M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$10.5M
$49.9M
Total Assets
$28.6M
$185.5M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFRI
BFRI
FBIO
FBIO
Q4 25
$6.4M
$79.4M
Q3 25
$3.4M
$86.2M
Q2 25
$7.2M
$74.4M
Q1 25
$1.8M
$91.3M
Q4 24
$5.9M
$57.3M
Q3 24
$2.9M
$58.9M
Q2 24
$4.4M
$76.2M
Q1 24
$3.8M
$83.8M
Total Debt
BFRI
BFRI
FBIO
FBIO
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
BFRI
BFRI
FBIO
FBIO
Q4 25
$10.5M
$49.9M
Q3 25
$-2.6M
$55.9M
Q2 25
$-4.7M
$43.9M
Q1 25
$500.0K
$22.3M
Q4 24
$4.4M
$22.7M
Q3 24
$5.5M
$21.2M
Q2 24
$10.9M
$17.9M
Q1 24
$-5.4M
$23.0M
Total Assets
BFRI
BFRI
FBIO
FBIO
Q4 25
$28.6M
$185.5M
Q3 25
$15.4M
$181.4M
Q2 25
$20.1M
$159.9M
Q1 25
$16.6M
$178.1M
Q4 24
$22.1M
$144.2M
Q3 24
$18.5M
$127.1M
Q2 24
$21.6M
$145.7M
Q1 24
$24.6M
$164.6M
Debt / Equity
BFRI
BFRI
FBIO
FBIO
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFRI
BFRI
FBIO
FBIO
Operating Cash FlowLast quarter
$-2.4M
$-12.5M
Free Cash FlowOCF − Capex
$-2.4M
FCF MarginFCF / Revenue
-13.9%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-0.42×
TTM Free Cash FlowTrailing 4 quarters
$-13.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFRI
BFRI
FBIO
FBIO
Q4 25
$-2.4M
$-12.5M
Q3 25
$-3.8M
$-6.1M
Q2 25
$-3.0M
$-27.6M
Q1 25
$-4.1M
$-19.6M
Q4 24
$-1.0M
$-12.9M
Q3 24
$-1.2M
$-20.1M
Q2 24
$-4.7M
$-21.8M
Q1 24
$-3.3M
$-25.4M
Free Cash Flow
BFRI
BFRI
FBIO
FBIO
Q4 25
$-2.4M
Q3 25
$-3.8M
Q2 25
$-3.0M
Q1 25
$-4.1M
Q4 24
$-1.0M
Q3 24
Q2 24
$-4.8M
Q1 24
$-3.4M
FCF Margin
BFRI
BFRI
FBIO
FBIO
Q4 25
-13.9%
Q3 25
-54.7%
Q2 25
-33.7%
Q1 25
-48.0%
Q4 24
-8.1%
Q3 24
Q2 24
-60.8%
Q1 24
-42.7%
Capex Intensity
BFRI
BFRI
FBIO
FBIO
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.0%
0.0%
Q2 24
0.6%
Q1 24
0.7%
Cash Conversion
BFRI
BFRI
FBIO
FBIO
Q4 25
-0.42×
Q3 25
-1.04×
Q2 25
-1.78×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons